Global Industry Analysts, Inc., Oct 2010, Pages: 435
and custom watermarks.
For information on site licence pricing please click on Enquire before buying HIV/AIDS TESTING
A GLOBAL STRATEGIC BUSINESS REPORT
Decision Resources, Inc., May 2010, Pages: 23
in the antiviral market.
Questions answered in this report:
- HIV/AIDS continues to be the most-studied infectious disease, and physicians surveyed by Decision Resources identified HIV/AIDS as the area of the most
Business Insights, Aug 2011, Pages: 100
Other drugs to fight HIV
Common adverse effects with antiretroviral therapy
Epidemiology of HIV/AIDSGlobal scenario
Seven major markets (7MM)
Forecast epidemiology
Global market analysis
Summary
Espicom Business Intelligence Ltd, Oct 2011, Pages: 72
of Tuberculosis, 1997-2006
Cancer
New Cases of Cancer by Primary Site and Sex, 2006
HIV/AIDSHIV/AIDS cases, 1984-2006
CHARTS
Map of Norway
Population by Age Group, 2008 (%)
NORWAY - HEALTHCARE SYSTEM
Decision Resources, Inc., March 2010, Pages: 35
in sub-Saharan Africa and Brazil; President’s Emergency Plan for AIDS Relief (PEPFAR); fi xed-dose combinations (FDCs); Indian manufacturers; access programs; HIV/AIDS; infl uenza; emergency use
VDM Publishing House, Nov 2009, Pages: 92
HIV/AIDS has become the most devastating global epidemic the world has ever faced and highly affecting young and economically active segment of the population. Effective behavioral change
UBM Canon, Aug 2010, Pages: 70
conditions such as HIV/AIDS, meningitis, and dengue. Even the seasonal influenza segment holds significant opportunities to improve market penetration, shelf stability, and delivery.
One of the most striking
ICON Group International, Jan 2011, Pages: 329
Market Potential Estimation Methodology Overview This study covers the world outlook for HIV/AIDS confirmatory tests across more than 2000 cities. For the year reported, estimates are given
ICON Group International, Jan 2011, Pages: 329
Market Potential Estimation Methodology Overview This study covers the world outlook for HIV/AIDS monitoring test across more than 2000 cities. For the year reported, estimates are given
ICON Group International, Jan 2011, Pages: 329
Market Potential Estimation Methodology Overview This study covers the world outlook for HIV/AIDS testing across more than 2000 cities. For the year reported, estimates are given for the latent
ICON Group International, Jan 2011, Pages: 56
3 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS 3.1 Disclaimers & Safe Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for HIV/AIDS
ICON Group International, Jan 2011, Pages: 56
3 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS 3.1 Disclaimers & Safe Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for HIV/AIDS Monitoring
ICON Group International, Jan 2011, Pages: 56
3 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS 3.1 Disclaimers & Safe Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for HIV/AIDS Testing
ICON Group International, Jan 2011, Pages: 54
PROVISIONS 3.1 Disclaimers & Safe Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for HIV/AIDS Confirmatory Tests in Asia & Oceana
ICON Group International, Jan 2011, Pages: 38
AGREEMENT PROVISIONS 3.1 Disclaimers & Safe Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for HIV/AIDS Monitoring Test in Asia
ICON Group International, Jan 2011, Pages: 38
AGREEMENT PROVISIONS 3.1 Disclaimers & Safe Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for HIV/AIDS Testing in Asia
ICON Group International, Jan 2011, Pages: 71
AGREEMENT PROVISIONS 3.1 Disclaimers & Safe Harbor 3.2 Icon Group International, Inc. User Agreement Provisions The 2011-2016 Outlook for HIV/AIDS Monitoring Test in Europe & the Middle East
ICON Group International, Jan 2011, Pages: 54
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for hiv/aids confirmatory tests is not actual or historic
